A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

PHASE1TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 24, 2017

Primary Completion Date

April 3, 2019

Study Completion Date

September 17, 2019

Conditions

Metastatic Castration-Resistant Prostate Cancer

Interventions

DRUG

PCUR - 101

PCUR-101 Capsules 25 mg are solid dosage forms for oral administration

Trial Locations (3)

Johns Hopkins University School of Medicine, Baltimore

Karmanos Cancer Institute, Detroit

University of Wisconsin Carbone Cancer Center, Madison